Disease Info Card

Primary Myelofibrosis

Information about Primary Myelofibrosis: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Primary Myelofibrosis

Most recent studies have shown that Primary Myelofibrosis shares some biological mechanisms with anemia, dysmyelopoietic-syndromes, extramedullary-hematopoiesis-(disorder), fibrosis, hematological-disease, hemorrhage, leukemia, leukemia-myelocytic-acute, lymphoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, metaplasia, myeloid-leukemia, myeloid-leukemia-chronic, myeloproliferative-disease, neoplasms, polycythemia, polycythemia-vera, thrombocythemia-essential, thrombocytosis.

Among the many pathways, these few ones have gauged particular interests from scientists studying Primary Myelofibrosis, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Growth, Cell Proliferation, Coagulation, Excretion, Fibroblast Proliferation, Hemopoiesis, Hemostasis, Hypersensitivity, Immune Response, Localization, Metaphase, Methylation, Pathogenesis, Phagocytosis, Platelet Activation, Platelet Aggregation, Regeneration, Secretion

Quite a number of genes have been found to play important roles in Primary Myelofibrosis, such as ABL1, ASXL1, BCR, CD34, EPO, EPX, FGF2, JAK1, JAK2, MPL, PAFAH1B1, PTH, SF3B1, STAT5B, THPO, TIMP1, VEGFA, YWHAE. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.